Dr. Lee is the founder and Chief Executive Officer of Teclison. Previously, Dr. Lee was Translation Medicine Lead of Oncology at Roche from 2011 through 2014, where he was the clinical program lead for a monoclonal antibody with indication in liver cancer, as well as a new lung cancer drug that succeeded in obtaining U.S. FDA Breakthrough Therapy Designation and eventual market approval. From 2008 through 2011, Dr. Lee served as the Director of Clinical Research, Oncology for Merck & Co. He is the inventor of all Teclison’s patents and previously was a physician scientist in hematology/oncology at Virginia Commonwealth University and in the Department of Pharmaceutics and Pharmaceutical Science at the University of Utah. Dr. Lee completed his medical oncology fellowship at the University of Washington and Fred Hutchinson Cancer Research Center, and his internal medicine residency at Duke University Hospital. Dr. Lee received his M.D. from National Taiwan University in Taiwan and his Ph.D. in biochemistry from Duke University.
.svg)
